NOHA Biomarker Detection for ER-Negative Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective indicators for early detection and monitoring of estrogen receptor-negative (ER−) breast cancer, particularly in aggressive subtypes, which are difficult to treat and exhibit ethnic disparity, leading to worse prognosis and higher mortality rates.
Innovation Solution
Development of a method using a NOHA antibody that immunospecifically binds to Nw-hydroxy-L-Arginine (NOHA), allowing for the detection of NOHA levels in samples to diagnose and monitor ER− breast cancer, assess treatment responsiveness, and identify therapeutic agents, through techniques such as immunoassays and ELISA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for breast cancer detection, then general breast cancer can be detected, but ER- breast cancer cannot be effectively detected or monitored due to lack of specific indicators
Solution Approach 1:
The patent uses NOHA as an intermediary biomarker that mediates between the tumor microenvironment and detectable signals. NOHA levels in plasma serve as a reliable indicator of ER- breast cancer presence and treatment response, enabling indirect but accurate detection of the disease state without requiring direct tumor sampling.
Solution Approach 2:
The patent replaces traditional mechanical/biopsy-based diagnostic methods with a biochemical detection system. Instead of physically examining tumor tissue, the invention uses immunoassays to detect NOHA levels in plasma, substituting a chemical/biochemical measurement system for mechanical tissue analysis.
2Ease of operation
If traditional monitoring methods are used for ER- breast cancer treatment, then general treatment can be administered, but treatment responsiveness cannot be accurately assessed
Solution Approach 1:
The patent implements a feedback mechanism where NOHA levels are measured before and during treatment to provide real-time information about treatment effectiveness. The change in NOHA levels feeds back to clinicians to determine whether to continue, adjust, or change the treatment regimen based on objective biomarker data.
Solution Approach 2:
The patent replaces subjective clinical assessment of treatment response with an objective biochemical measurement system. Instead of relying on physical examinations or imaging, the invention uses immunoassay-based detection of NOHA levels to precisely measure treatment responsiveness.
3Adaptability or versatility
If general breast cancer treatment protocols are used, then standard care can be provided, but personalized therapy for ER- breast cancer cannot be achieved
Solution Approach 1:
The patent applies local quality by tailoring treatment to the specific molecular characteristics of ER- breast cancer. Instead of uniform treatment protocols, the invention uses NOHA biomarker levels to identify and treat specific patient subgroups with targeted therapies, providing locally optimized treatment quality for each patient's disease phenotype.
Solution Approach 2:
The patent uses parameter changes in NOHA levels to guide treatment decisions. By monitoring changes in this biochemical parameter over time, the system adapts treatment parameters (drug selection, dosage, timing) to match the patient's evolving disease state, enabling dynamic personalized therapy adjustment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a sensitive and reliable biomarker for ER− breast cancer prognosis, enabling early detection, monitoring of treatment efficacy, and personalized therapy, with ethnic specificity improving diagnostic precision and treatment outcomes.
Implementation Method 1
an antibody that immunospecifically binds to HOHA, and anti-binding fragments thereof
Data Source
AI summary
Methods and diagnostic compositions for monitoring ER− breast cancer are disclosed. In some aspects, a method for detecting ER− breast cancer in a subject comprises obtaining a subject sample from a subject suffering from breast cancer; determining a level of NOHA in the subject sample; and comparing the level of NOHA obtained from the subject sample to the level of NOHA in a control sample, wherein a lower level of NOHA in the subject sample indicates presence of ER− breast cancer in the subject.